MARKET

SVRA

SVRA

Savara Inc
NASDAQ
5.77
+0.23
+4.15%
After Hours: 5.77 0 0.00% 16:10 01/07 EST
OPEN
5.60
PREV CLOSE
5.54
HIGH
5.88
LOW
5.60
VOLUME
1.45M
TURNOVER
--
52 WEEK HIGH
7.01
52 WEEK LOW
1.890
MARKET CAP
1.17B
P/E (TTM)
-10.7850
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SVRA last week (1229-0102)?
Weekly Report · 2d ago
Weekly Report: what happened at SVRA last week (1222-1226)?
Weekly Report · 12/29/2025 09:21
Savara (SVRA): Reassessing Valuation After MOLBREEVI BLA Resubmission and Priority Review Request
Simply Wall St · 12/25/2025 21:19
Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 12/23/2025 13:17
Guggenheim Remains a Buy on Savara (SVRA)
TipRanks · 12/23/2025 12:16
Savara Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/23/2025 11:52
Savara Price Target Raised to $10.00/Share From $8.00 by HC Wainwright & Co.
Dow Jones · 12/23/2025 11:52
HC Wainwright & Co. Maintains Buy on Savara, Raises Price Target to $10
Benzinga · 12/23/2025 11:44
More
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Webull offers Savara Inc stock information, including NASDAQ: SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.